• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[巴西人群中用于治疗系统性动脉高血压和2型糖尿病的药物可及性:来自2019年巴西全国健康调查的数据]

[Access to medicines for the treatment of systemic arterial hypertension and type 2 diabetes mellitus in the Brazilian population: data from the 2019 Brazilian National Health Survey].

作者信息

Leal Adriana Amorim de Farias, Galvão Maria Helena Rodrigues, Roncalli Ângelo Giuseppe

机构信息

Universidade Federal do Rio Grande do Norte, Natal, Brasil.

Centro Universitário Unifacisa, Campina Grande, Brasil.

出版信息

Cad Saude Publica. 2024 Sep 16;40(8):e00241022. doi: 10.1590/0102-311XPT241022. eCollection 2024.

DOI:10.1590/0102-311XPT241022
PMID:39292136
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11405024/
Abstract

This study aimed to measure access to medicines for the treatment of systemic arterial hypertension and type 2 diabetes mellitus in Brazil according to the mode of acquisition, as well as to analyze the factors associated with this access, based on data from the 2019 Brazilian National Survey of Health (PNS, acronym in Portuguese). Socioeconomic data and data related to the use of medicines by people aged 15 and over were analyzed in relation to access via the Brazilian Popular Pharmacy Program (PFPB, acronym in Portuguese) and via public services. The majority of Brazilians who took part in the PNS reported using medication to control hypertension in the previous 15 days (91.5%) and using oral medication for diabetes (95.2%) and/or insulin (70%). Most participants obtained oral medication for hypertension and type 2 diabetes mellitus via PFPB (45.2% and 53.6%, respectively), and the factors that most negatively influenced this access were older age, lower income, lower schooling, very poor self-rated health and not having private health insurance. Access to insulin, on the other hand, was most often via the public health service (69.7%), and the factors that most negatively influenced this access were black/mixed-race skin color, lower income, very poor self-rated health and not having private health insurance. Generally, the importance of the PFPB as a policy to increase access to essential medicines in Brazil was highlighted, considering the free supply of antihypertensive and antidiabetic drugs.

摘要

本研究旨在根据获取方式,衡量巴西治疗系统性动脉高血压和2型糖尿病药物的可及性,并基于2019年巴西全国健康调查(PNS,葡萄牙语缩写)的数据,分析与这种可及性相关的因素。分析了15岁及以上人群的社会经济数据以及与药物使用相关的数据,涉及通过巴西大众药房计划(PFPB,葡萄牙语缩写)和公共服务获取药物的情况。参与PNS的大多数巴西人报告称,在过去15天内使用药物控制高血压(91.5%),使用口服药物治疗糖尿病(95.2%)和/或胰岛素(70%)。大多数参与者通过PFPB获得高血压和2型糖尿病的口服药物(分别为45.2%和53.6%),对这种获取产生最大负面影响的因素是年龄较大、收入较低、受教育程度较低、自我评估健康状况很差以及没有私人健康保险。另一方面,胰岛素的获取最常通过公共卫生服务(69.7%),对这种获取产生最大负面影响的因素是黑人/混血肤色、收入较低、自我评估健康状况很差以及没有私人健康保险。总体而言,考虑到免费供应抗高血压和抗糖尿病药物,PFPB作为一项增加巴西基本药物可及性的政策的重要性得到了凸显。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83b9/11405024/31f2bb5ab572/1678-4464-csp-40-08-PT241022-gf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83b9/11405024/31f2bb5ab572/1678-4464-csp-40-08-PT241022-gf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83b9/11405024/31f2bb5ab572/1678-4464-csp-40-08-PT241022-gf1.jpg

相似文献

1
[Access to medicines for the treatment of systemic arterial hypertension and type 2 diabetes mellitus in the Brazilian population: data from the 2019 Brazilian National Health Survey].[巴西人群中用于治疗系统性动脉高血压和2型糖尿病的药物可及性:来自2019年巴西全国健康调查的数据]
Cad Saude Publica. 2024 Sep 16;40(8):e00241022. doi: 10.1590/0102-311XPT241022. eCollection 2024.
2
Access to and use of high blood pressure medications in Brazil.巴西高血压药物的获取与使用情况。
Rev Saude Publica. 2016 Dec;50(suppl 2):8s. doi: 10.1590/S1518-8787.2016050006154.
3
Use of antihypertensive and antidiabetic medications in Brazil: an analysis of socioeconomic differences. National Health Survey, 2013.巴西抗高血压和抗糖尿病药物的使用情况:社会经济差异分析。2013年全国健康调查
Rev Bras Epidemiol. 2019 Oct 7;22Suppl 02(Suppl 02):E190014.SUPL.2. doi: 10.1590/1980-549720190014.supl.2. eCollection 2019.
4
[Sources of medicines for hypertension and diabetes in Brazil: telephone survey results from Brazilian state capitals and the Federal District, 2011].[巴西高血压和糖尿病药物的来源:2011年巴西各州首府和联邦区的电话调查结果]
Cad Saude Publica. 2016 Feb;32(2):e00090014. doi: 10.1590/0102-311X00090014. Epub 2016 Feb 23.
5
[Obtaining drugs for hypertension and diabetes through the Brazilian People's Pharmacy Program: results of the National Health Survey, 2013].[通过巴西人民药房计划获取高血压和糖尿病药物:2013年全国健康调查结果]
Epidemiol Serv Saude. 2016 Jan-Mar;25(1):33-44. doi: 10.5123/S1679-49742016000100004.
6
Prevalence of use and sources of antihypertensive medicine in Brazil: an analysis of the VIGITEL telephone survey.巴西抗高血压药物的使用 prevalence 及来源:基于 VIGITEL 电话调查的分析
Rev Bras Epidemiol. 2020;23:e200028. doi: 10.1590/1980-549720200028. Epub 2020 May 11.
7
Access to medicines for hypertension: a survey in rural Yogyakarta province, Indonesia.印度尼西亚日惹省农村地区高血压药物的可及性:一项调查
Rural Remote Health. 2018 Aug;18(3):4393. doi: 10.22605/RRH4393. Epub 2018 Aug 15.
8
Impacts of a Brazilian pharmaceutical program on the health of chronic patients.巴西一项制药计划对慢性病患者健康的影响。
Rev Saude Publica. 2019 Jan 31;53:20. doi: 10.11606/S1518-8787.2019053000733.
9
Access to medicines for chronic diseases in Brazil: a multidimensional approach.巴西慢性病药品的可及性:一种多维度方法。
Rev Saude Publica. 2016 Dec;50(suppl 2):6s. doi: 10.1590/S1518-8787.2016050006161.
10
Sources of medicines for hypertension and diabetes in Brazil: results from the National Health Survey.巴西高血压和糖尿病药物的来源:全国健康调查结果
Cad Saude Publica. 2022 Oct 17;38Suppl 1(Suppl 1):e00152721. doi: 10.1590/0102-311X00152721. eCollection 2022.

本文引用的文献

1
The burden of Noncommunicable Diseases in Portuguese Language Countries.葡萄牙语国家的非传染性疾病负担。
Cien Saude Colet. 2023 May;28(5):1549-1562. doi: 10.1590/1413-81232023285.11622022. Epub 2022 Oct 27.
2
Sources of medicines for hypertension and diabetes in Brazil: results from the National Health Survey.巴西高血压和糖尿病药物的来源:全国健康调查结果
Cad Saude Publica. 2022 Oct 17;38Suppl 1(Suppl 1):e00152721. doi: 10.1590/0102-311X00152721. eCollection 2022.
3
National Health Survey 2019: medication obtainment through the Brazilian Popular Pharmacy Program by adults being treated for hypertension and diabetes.
2019 年全国健康调查:巴西平价药房计划为高血压和糖尿病患者提供药物的情况。
Epidemiol Serv Saude. 2022 Jul 6;31(spe1):e2021366. doi: 10.1590/SS2237-9622202200004.especial. eCollection 2022.
4
Monitoring the goals of the plans for coping with Chronic Non-Communicable Diseases: results of the National Health Survey, Brazil, 2013 and 2019.监测应对慢性非传染性疾病计划目标:2013 年和 2019 年巴西国家卫生调查结果。
Epidemiol Serv Saude. 2022 Jul 6;31(spe1):e2021364. doi: 10.1590/SS2237-9622202200008.especial. eCollection 2022.
5
Public policy coverage and access to medicines in Brazil.巴西的公共政策覆盖范围与药品可及性。
Rev Saude Publica. 2022 Jun 24;56:58. doi: 10.11606/s1518-8787.2022056003898. eCollection 2022.
6
[Inequalities in risk behaviors for chronic noncommunicable diseases: Vigitel, 2019].[慢性非传染性疾病风险行为的不平等现象:2019年巴西成人健康调查]
Cad Saude Publica. 2022 Jun 27;38(6):e00273520. doi: 10.1590/0102-311XPT273520. eCollection 2022.
7
Status of the main noncommunicable diseases and lifestyles in the Brazilian population: Brazilian National Health Survey, 2013 and 2019.巴西人群中主要非传染性疾病和生活方式的状况:2013年和2019年巴西全国健康调查
Cad Saude Publica. 2022 May 6;38Suppl 1(Suppl 1):PT276021. doi: 10.1590/0102-311XPT276021. eCollection 2022.
8
The Family Health Strategy coverage in Brazil: what reveal the 2013 and 2019 National Health Surveys.巴西家庭健康战略覆盖情况:2013 年和 2019 年全国健康调查揭示的内容。
Cien Saude Colet. 2021 Jun 14;26(suppl 1):2543-2556. doi: 10.1590/1413-81232021266.1.43952020. eCollection 2021.
9
National Health Survey 2019: history, methods and perspectives.2019 年全国健康调查:历史、方法和展望。
Epidemiol Serv Saude. 2020 Oct 5;29(5):e2020315. doi: 10.1590/S1679-49742020000500004. eCollection 2020.
10
Assessment of premature mortality for noncommunicable diseases.非传染性疾病过早死亡率评估
Rev Bras Enferm. 2020 Mar 9;73(2):e20180440. doi: 10.1590/0034-7167-2018-0440. eCollection 2020.